Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (295)	3/19/1998 11:23:00 AM
From: SC	Read Replies (2) \| Respond to of 1321

I wonder if 2.5 million refers to the number of eyes or the number of people? A large proportion of the folks who develop this problem in one eye eventually have the same problem in the other eye. Is the phase IIIb trial designed to demonstrate the safety and efficacy of repeated treatments? The subretinal neovascular membranes virtually disappear within a week or so of treatment but recur within about 12 weeks (hence the mention of repeated treatments in your link). This appears to be an excellent treatment but unfortunately will evidently need to be repeated on an ongoing basis as it is not a cure(I suppose from an investment standpoint this might be looked on as favorable). If the new trial is not designed to demonstrate safety and efficacy of ongoing repeated treatments, the FDA is likely to demand more data. Since this is a terribly debilitating disease and there is no currently effective cure or good treatment, this is looking like a breakthrough treatment if the repeated treatments are acceptable to the FDA. sc